Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA
Analysis from. | May 11, 2023
First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of. | May 11, 2023
11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant .
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.